PT-141 peptide: Benefits, side effects, dosage details, and how it works
We examine the science and side effects of PT-141 to determine whether it’s a safe and effective solution for sexual health.
Photo by Innerbody Research
In one of the Cleveland Clinic’s recent National MENtion It® surveys, 37% of American men stated that they’ve experienced issues related to sexual health, not only preventing them from enjoying intercourse with their partners but also creating a tremendous amount of shame and anxiety.1 2 Moreover, in about 40% of cases, even the most well-known and effective treatments fail to produce a satisfactory response owing to side effects or ineffectiveness.13
In those cases, the peptide PT-141 has shown some promise as an unconventional alternative or adjunct treatment. It’s nowhere near as mainstream as other men’s sexual health medications, and it works by a much different mechanism of action: rather than affecting blood flow, PT-141 works on desire and arousal pathways in the brain. So, with this guide, our goal is to examine whether its mechanism offers any advantage over the vasodilatory actions of something like Viagra or Cialis, as well as to help you determine whether it’s a viable option for you.
And if it is, we recommend exploring your candidacy with UVG Health.
UVG Health offers an expansive selection of pharmaceutical-grade peptides, including PT-141 in various forms.
Every order request is reviewed by an independent licensed physician or nurse practitioner, and prescriptions are fulfilled by state-licensed 503A compounding pharmacies. UVG also hosts several resources to help the peptide-curious better understand their treatment options, including an online quiz for building your protocol and a free call with the platform’s care navigator, Annabeth, a thoroughly attentive and knowledgeable guide in your treatment journey.
Jump to:
In this Review
Why you should trust us
At Innerbody Research over the past two decades, we have helped tens of millions of readers like you make more informed decisions to live healthier lives. Our research and experience in the men’s sexual health space is particularly expansive.
This guide to PT-141 builds on our thousands of research hours on male sexual health, as well as the 1,000+ hours we’ve devoted so far to therapeutic peptides. Our efforts have extended beyond reading the scientific literature, too. They have involved discussions with doctors who prescribe peptides and people who use them, along with a thorough survey of the peptide marketplace to identify reputable telehealth platforms.
Additionally, like all health-related content on this website, this assessment of PT-141 was thoroughly vetted by one or more members of our Medical Review Board for accuracy. We’ll continue monitoring developments on PT-141 to keep our readers up to date.
What is PT-141?
PT-141 (a.k.a. bremelanotide) is a cyclic heptapeptide analog and melanocortin receptor agonist (MRA) — a synthetic version of a natural chain of seven amino acids that activates melanocortin. That is, it binds to receptors in the body that typically control pigmentation, among other things.
One of those other things, it turns out, is sexual performance. In the early 2000s, as researchers were testing potential sunless tanning agents, they noted that MRAs, more than placebos, were dose-dependently associated with erections in trial subjects. They hence concluded that one of the tanning agents, melanotan II, could possibly treat erectile dysfunction (ED).
In the years that followed, researchers isolated a melanotan II derivative that they believed was the primary driver of the erection side effect. This is the peptide that came to be known as PT-141.
PT-141 then entered trials to treat ED.3 Early trials were mostly successful, but it took nearly 20 years for the drug to gain FDA approval and hit the market in any form. The reason for the long wait isn’t entirely clear, but the ED program is generally reported to have stalled over blood-pressure increases associated with a nasally administered form.
When PT-141 finally hit the prescription market, it was released as Vyleesi, an injectable intended not for men with ED but for premenopausal women who’ve lost their sexual desire (i.e., women with hypoactive sexual desire disorder).4 12 As of this writing, the United States Food & Drug Administration (FDA) has not approved PT-141 for the treatment of ED, although it can be obtained as an off-label ED treatment — injectable or intranasal — through certain prescription channels.
How does PT-141 work?
PT-141 works differently from PDE5 inhibitors such as sildenafil (Viagra) and tadalafil (Cialis). Instead of increasing blood flow, it acts on melanocortin receptors in the brain involved in sexual desire and arousal — specifically in the hypothalamus, which plays a key role in regulating erectile function.6 Further distinguishing it from PDE5 inhibitors like Viagra is that it may initiate erections without visual sexual stimulation.7
Interestingly, PT-141 is FDA-approved, under the brand name Vyleesi, not for men’s sexual health but for low sexual desire in premenopausal women. Still, providers may prescribe it off-label for men, in compounded form, which is not the same product as Vyleesi and is not FDA-approved.
One of the more compelling early studies on PT-141’s efficacy for ED, published in 2004, involved healthy men who had responded inadequately to sildenafil (Viagra). In the randomized, double-blind crossover trial, subcutaneous 4mg and 6mg injections of PT-141 were well-tolerated and produced “statistically significant erectile response.” The researchers hence concluded that “PT-141 may provide an alternative treatment for ED with a potentially broad patient base.”5
Another 2004 study reported positive outcomes, as well. Under placebo-controlled conditions, men who received PT-141 doses above 7mg experienced statistically significant erectile responses compared with placebo, with onset of the first erection occurring within 30 minutes.14
A more recent, albeit more scope-limited, study broadly corroborates the 2004 outcomes. This one, published in 2024, followed PT-141 prescription-dispensing data from a single clinic and involved interviews with the men who had taken the drug between 2019 and 2023. Among the findings:17
- 76% of men were “more satisfied with their lovemaking and duration of lovemaking”
- 83% said “vaginal insertion was easier”
- 65% found it was easier to orgasm
- 56% found orgasms to be more pleasurable
- 65% found that “lovemaking was more pleasurable”
- 71% found that “the partner’s overall experience was more pleasurable”
- 76% were “more at ease” about initiating lovemaking
For all that, a question remains as to PT-141’s overall utility as an ED remedy compared with PDE5 inhibitors. It is, for instance, significantly shorter-lasting than sildenafil — approximately 2-3 hours versus 4-5 hours.9 15 16 Therefore, even in responsive users, the window of opportunity for sexual intercourse would be very narrow. Optimistic planning, or at least judicious timing, would be necessary to take full advantage of the drug’s effects.
The duration problem might be mitigated via coadministration with a PDE5 inhibitor, which yielded good results in a small 2005 study.8 Yet research on this approach remains limited. A phase 2 clinical study on such coadministration has been conducted by the biopharmaceutical company Palatin, but its results were unavailable at the time of this writing.18
Is PT-141 safe?
In the context of ED, the first thing to understand about PT-141’s safety profile is that it’s incomplete. The body of research literature is currently too meager to say for certain whether PT-141 presents undue health concerns to men with erectile performance issues, such that high-authority health entities like the Mayo Clinic and MedlinePlus outright say that it isn’t indicated for anyone who isn’t a premenopausal woman with hypoactive sexual desire disorder.19 20 Any use outside of that narrow population subset would be off-label.
That said, we can draw some conclusions about PT-141’s safety from the relatively little research available to us.
The most vigorous nod in PT-141’s favor — apart from studies that have reported it to be “well tolerated” among research subjects5 — is that it hypothetically poses less cardiovascular risk than better-studied ED drug alternatives. Whereas Viagra and Cialis are known to widen blood vessels and lower blood pressure, PT-141’s mechanism of action suggests it would have no such hemodynamic effect.10 Somewhat corroborating this supposition is a 2020 study in women that showed negligible effects on blood pressure.11 Therefore (and, again, in theory), it could serve as a substitute ED medication for men with heart conditions.
At the same time, Vyleesi’s labeling notes transient blood-pressure increases and advises against use with uncontrolled hypertension or known cardiovascular disease, so the theoretically lower cardiovascular risk has yet to be borne out in practice.
Moreover, the available research describes a wide range of adverse effects associated with PT-141 in both injectable and intranasal forms. The most common of these are those shared by many therapeutic peptides: nausea, flushing, headache, and injection site reactions. Less commonly, however, it may also cause severe nausea and vomiting, arthralgia, restless leg syndrome, skin color changes, and (again in contradiction to the theory we’ve discussed) transient blood pressure increases.21 The likelihood and severity of these side effects may be dose- and duration-dependent; the stronger your dose and the longer you use the drug, the higher your risk of experiencing serious adverse events may be.
Research-grade vs. pharmaceutical-grade PT-141
Your risk of experiencing adverse events also hinges on whether your peptide is research-grade or pharmaceutical-grade.
Research-grade peptides are nonprescription products intended for laboratory use only.
Pharmaceutical-grade peptides are the opposite: prescription medications deemed suitable for human consumption.
The factor that distinguishes one from the other is purity. Because research-grade peptides are intended for cell cultures and animal models, it’s less impactful if they contain a high concentration of contaminants, which they often do. Some research-grade substances have purity levels as low as 60%.22 If you were to introduce such a substance into your body, your immune system could interpret it as a threat and mount a potentially life-threatening response — a state called immunogenicity.23
But with pharmaceutical-grade peptides, you’re dealing with purity levels of at least 98-99%. Having an exponentially lower concentration of contaminants, they pose much less risk of immunogenicity.
What’s it like to use PT-141?
Because PT-141 isn’t FDA-approved for men or ED, the treatment protocol isn’t easily described in sweeping terms. But based on what we know about it and other peptides, we can deduce what an “ordinary” regimen might look like.
Route of administration
PT-141, like most therapeutic peptides, can be administered via subcutaneous injection, but it’s also available as an intranasal spray. Injectable peptides used to require reconstituting dry peptide powder with bacteriostatic water, but it’s more common now to see premixed solutions instead. Intranasal peptides have never required such prep.
Dose
We’ve seen PT-141 offered at a 20mg intranasal dose, which is roughly consistent with the amounts used in clinical research. Injectable forms may start much lower, around 1-2mg. Your provider, however, may adjust your dose based on your history, needs, and individual response to the drug.
Dose frequency
Unlike many peptides, which follow fixed dosing schedules, PT-141 should be taken as needed, ideally at least 30 minutes before you plan to have sexual intercourse.
Storage
Peptides should be stored in a cold, dry environment to slow their degradation. A refrigerator, in other words. The same goes for intranasal forms, generally.
Who is (and is not) a candidate for PT-141?
As of this writing, premenopausal women with hypoactive sexual desire disorder are the only FDA-approved cohort for PT-141. At the same time, as an off-label treatment, PT-141 may also be suited for men with ED who have been nonresponsive to traditional ED medications, namely PDE5 inhibitors.
Some research suggests that for men with cardiovascular health concerns, PT-141 may serve as an alternative to PDE5 inhibitors, but we wouldn’t go so far as to recommend it as such. For one thing, recall that blood pressure spikes are among PT-141’s less common but severe side effects. For another, many prescribers consider a cardiovascular history to be a contraindicated health condition.
Keep in mind, too, that PT-141 is effectively an experimental treatment for ED. Its effects in this area are therefore unproven, so you should temper your expectations. You may not see the outcomes you’re hoping for.
Where to find PT-141
If you’ve tried and not responded to Viagra, Cialis, or their generic forms, your primary care physician may consider writing you an off-label prescription for PT-141, but the likelihood may depend on their familiarity with the peptide and their willingness to recommend an experimental treatment.
A dedicated peptide clinic is a better bet. Search online, and you may find there’s at least one in your city or town.
Alternatively, you can seek out a telehealth platform that ships pharmaceutical-grade peptides to your location. Relatively few of them offer PT-141, and among those that do, not all are reputable. Before you commit to a purchase, you’ll want to correspond with a representative to gauge the platform’s trustworthiness. Primarily, make sure it deals in pharmaceutical-grade products. Otherwise, you may open yourself up to an untenable level of risk.
With that in mind, our experience with various options leads us to recommend UVG Health at this time for those who are interested in pursuing PT-141. UVG Health is a LegitScript-certified platform that works with state-licensed 503A compounding pharmacies to deliver prescription, pharmaceutical-grade peptides to your door.
UVG Health carries PT-141 in several forms:
- Stand-alone injection: available in all 50 states
- Stand-alone nasal spray: available in all states except Arkansas, California, Indiana, and Minnesota
- Oral dissolving tablet stacked with tadalafil (Cialis) and oxytocin: available in all states except Alabama
- Nasal spray stacked with tadalafil (Cialis) and oxytocin: available in all 50 states
When you order from UVG Health, an independent licensed physician or nurse practitioner reviews your request and determines whether you’re suited for treatment. Only after your prescription is approved are you charged for your order.
For those who aren’t yet sure about trying PT-141, a quick discovery call with UVG’s care navigator, Annabeth, should clarify your path forward. We ourselves have consulted Annabeth, whose comprehensive knowledge of therapeutic peptides has helped team members choose treatments that align with their health goals. The call is free, quick, and enlightening.
Sources
Innerbody uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
Cleveland Clinic. (2023). Cleveland Clinic survey examines the current state of men’s health in America. Cleveland Clinic.
Sheng, Z. (2021), Psychological consequences of erectile dysfunction. Trends Urology & Men Health, 12, 19-22.
Molinoff, P. B., et al. (2003). PT-141: A melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 994, 96-102.
Dhillon, S., & Keam, S. J. (2019). Bremelanotide: First approval. Drugs, 79(14), 1599-1606.
Rosen, R., et al. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra®. International Journal of Impotence Research, 16, 135-142.
Argiolas, A., & Melis, M. R. (2005). Central control of penile erection: role of the paraventricular nucleus of the hypothalamus. Progress in Neurobiology, 76(1), 1-21.
El-Achkar, A., et al. (2026). Peptides for sexual dysfunction: What clinicians should know. American Urological Association.
Diamond, L. E., et al. (2005). Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology, 65(4), 755-759.
Rose, R. C., et al. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International Journal of Impotence Research, 16(2), 135-142.
Prisant L. M. (2006). Phosphodiesterase-5 inhibitors and their hemodynamic effects. Current Hypertension Reports, 8(4), 345-351.
White, W., et al. (2020). Effect of bremelanotide on ambulatory blood pressure when administered for up to 16 consecutive days. Obstetrics & Gynecology, 135, 21S-21S.
U.S. Food and Drug Administration. (2019). FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. FDA.
Cleveland Clinic. (2025). Erectile dysfunction: What are the options when PDE5 inhibitors fail? Cleveland Clinic.
Diamond, L. E., et al. (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research, 16(1), 51-59.
King, S. H., et al. (2007). Melanocortin receptors, melanotropic peptides and penile erection. Current Topics in Medicinal Chemistry, 7(11), 1098-1106.
Eardley, I., et al. (2002). Onset and duration of action of sildenafil for the treatment of erectile dysfunction. British Journal of Clinical Pharmacology, 53(Suppl. 1), 61S-65S.
Goldstein, S. W., Goldstein, I. (2024) Use of bremelanotide in men with sexual dysfunction at a sexual medicine clinic. The Journal of Sexual Medicine, 21(Suppl. 6), qdae161.029.
Palatin. (2024). Palatin announces the initiation of a Phase 2 clinical study of bremelanotide co-administered with a PDE5i for the treatment of erectile dysfunction (ED). Palatin.
Mayo Clinic. (2026). Bremelanotide (Subcutaneous route). Mayo Clinic.
MedlinePlus. (2019). Bremelanotide injection. National Library of Medicine.
National Institute of Diabetes and Digestive and Kidney Diseases. (2021). bremelanotide. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].
De Groot, A. S., et al. (2023). Immunogenicity risk assessment of synthetic peptide drugs and their impurities. Drug Discovery Today, 28(10), 103714.
United States Food & Drug Administration. (2024). Immunogenicity of protein-based therapeutics. FDA.
READ THIS NEXT
Copyright © Innerbody Research 1997 - 2025. All Rights Reserved.
